Cellebrite DI Ltd. (NASDAQ:CLBT) Receives $22.50 Consensus PT from Analysts

Cellebrite DI Ltd. (NASDAQ:CLBT) has received a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $22.50.

CLBT has been the subject of a number of analyst reports. Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Needham & Company LLC decreased their price target on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 12th.

Institutional Trading of Cellebrite DI

A number of hedge funds have recently made changes to their positions in CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Cellebrite DI by 16.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock valued at $3,362,000 after buying an additional 24,881 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Cellebrite DI by 16.2% in the second quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock valued at $5,029,000 after buying an additional 43,898 shares during the last quarter. Invesco Ltd. lifted its position in shares of Cellebrite DI by 6.4% in the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after buying an additional 209,473 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of Cellebrite DI in the second quarter valued at approximately $341,000. Finally, Marshall Wace LLP acquired a new stake in shares of Cellebrite DI in the second quarter valued at approximately $4,472,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Stock Up 2.5%

CLBT stock opened at $13.32 on Monday. The business has a 50 day moving average price of $13.57 and a two-hundred day moving average price of $15.90. The company has a market cap of $3.32 billion, a price-to-earnings ratio of 42.98, a P/E/G ratio of 1.99 and a beta of 1.15. Cellebrite DI has a twelve month low of $11.02 and a twelve month high of $20.53.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.14. The firm had revenue of $128.82 million during the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The business’s revenue was up 28.8% compared to the same quarter last year. During the same period last year, the company earned $0.10 earnings per share. On average, equities research analysts anticipate that Cellebrite DI will post 0.43 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.